ClinicalTrials.gg
CompletedNCT04400409Updated Feb 8, 2024

Implementation of Vascular Care Team to Improve Medical Management of PAD Patients

An interventional study of Intervention A - Vascular Care + site 6MWT administration and Intervention B - Standard Care + site 6MWT administration in Peripheral Artery Disease, sponsored by Colorado Prevention Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Colorado Prevention Center · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
94th of 373
166 · median 64
Started
2020
with 28 others
No phase
217 of 479
40 open now
Registered
339th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 94th largest by enrollment of the 373 interventional ones that give a count, is one of 29 that started in 2020, is one of 217 with no phase, and was the 339th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This study intends to evaluate the efficacy of a multidisciplinary vascular care team utilizing an intensive guideline-based lipid reduction program in improving risk factor modification as measured by LDL-C reduction at 12 months in patients with peripheral artery disease (PAD). An additional objective is to understand the potential reach and impact if this program were extended across the University of Colorado Healthcare (UC Health) System.

Read the detailed description

Patients with PAD and elevated LDL-C who are cared for at the University of Colorado (UC) and who provide consent will be randomized 1:1 to Intervention A, a vascular care team approach including pharmacy and healthcare provider assistance with medication adherence, versus Intervention B consisting of standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood. In order to investigate the efficacy of the CPC Endpoint Quality Intervention Program (EQuIP), subjects will additionally be randomized 1:1 to an investigative site conducted Six-Minute Walk Test or an EQuIP team led Six-Minute Walk Test. Quality of Life data will be collected from all subjects. There will also be an observational cohort (registry) to understand current practice patterns and outcomes in a non-interventional PAD population within the UC Health system in order to assess the potential impact of Intervention A after conclusion of the randomized study.

03

Conditions studied

  • Peripheral Artery Disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented lower extremity atherosclerotic PAD with recommended goal LDL-C \<70 mg/dL by the ACC/AHA Management of Blood Cholesterol Guidelines
  2. Receiving care at CU Anschutz
  3. Screening/baseline LDL-C ≥70 mg/dL without change in lipid lowering therapy within the last 30 days prior to LDL-C draw.
  4. Able to provide and willing to participate

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unlikely to remain in the UC Health system through 1 year follow up (12 months after randomization)
  2. \< 12 months
  3. Fasting triglycerides >400 mg/ml at screening
  4. End-stage renal disease (eGRF\<15 mL/min/1.73m2 and/or renal replacement therapy)
  5. History of nephrotic syndrome
  6. Clinical evidence of severe liver disease or another medical condition for which lipid lowering therapy may be
  7. Current enrollment in another device or drug study with unapproved devices or therapies or with therapies that would impact lipid levels or lipid therapy
  8. Any other condition that in the opinion of the investigator would make the subject unable to comply with the protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Active comparator
    Intervention A + site 6MWT administration

    Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence. 6-Minute Walk Test (6MWT) will be administered by site staff.

    Other: Intervention A - Vascular Care + site 6MWT administration

  • Active comparator
    Intervention B + site 6MWT administration

    Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood. 6-Minute Walk Test (6MWT) will be administered by site staff.

    Other: Intervention B - Standard Care + site 6MWT administration

  • Active comparator
    Intervention A + CPC EQuIP 6MWT administration

    Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence. 6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff.

    Other: Intervention A - Vascular Care + CPC EQuIP 6MWT administration

  • Active comparator
    Intervention B + CPC EQuIP 6MWT administration

    Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood. 6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff.

    Other: Intervention B - Standard Care + CPC EQuIP 6MWT administration

Interventions

  • OtherIntervention A - Vascular Care + site 6MWT administration

    Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

  • OtherIntervention B - Standard Care + site 6MWT administration

    Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

  • OtherIntervention A - Vascular Care + CPC EQuIP 6MWT administration

    Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

  • OtherIntervention B - Standard Care + CPC EQuIP 6MWT administration

    Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

06

What researchers measure

Primary outcomes

  1. Month 12 LDL-C

    Percent change from baseline to month 12 in LDL-C

    Time frame: 12 months

Secondary outcomes

  1. Month 6 LDL-C

    Percent change from baseline at 6 months in LDL-C

    Time frame: 6 months

Other outcomes

  1. EQ-5D-5L Quality of Life questionnaire

    Change from Baseline at months 6 and 12 in the EQ-5D-5L quality of life questionnaire.

    Time frame: 6 and 12 months

  2. Walking Impairment

    Change from Baseline at months 6 and 12 in the Walking Impairment Questionnaire (WIQ)

    Time frame: 6 and 12 months

  3. Distance Walked

    Change from Baseline at months 6 and 12 in the distance walked using the 6MWT.

    Time frame: 6 and 12 months

  4. Medication adherence

    Proportions of subjects at months 6 and 12 adherent to lipid-lowering therapy, determined by self-reporting

    Time frame: 6 and 12 months

  5. Biomarker levels

    Change from Baseline at 12 months in the levels of biomarkers (e.g. C-reactive protein \[CRP\], troponin, brain natriuretic peptide \[BNP\], lipoprotein(a) \[Lp(a)\])

    Time frame: 12 months

  6. Time to endpoint events

    Time from Baseline to: 1. Major adverse cardiovascular events (MACE) (myocardial infarction \[MI\], ischemic stroke, or cardiovascular death) or major adverse limb event (MALE) (major amputation or acute limb ischemia); 2. MACE 3. MALE 4. Lower extremity revascularization; 5. Coronary artery revascularization; 6. Death; 7. Any hospitalization

    Time frame: Time to event, up to 12 months

  7. Impact of CPC EQuIP process

    Impact of CPC EQuIP process on variability in 6MWT at 6 and 12 months

    Time frame: 6 and 12 months

  8. Correlation between venipuncture and dried dried blood spots

    Correlation between venipuncture and dried blood spot values of Baseline lipid and CRP levels

    Time frame: 12 months

07

Study locations

1 site
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
08

References and documents

Publications

  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10. No abstract available. Erratum In: J Am Coll Cardiol. 2019 Jun 25;73(24):3234-3237. doi: 10.1016/j.jacc.2019.05.012. PubMed 30423391 ↗
  • Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. PubMed 29133605 ↗
  • Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005 Sep;42(3):456-64; discussion 464-5. doi: 10.1016/j.jvs.2005.05.001. PubMed 16171587 ↗
  • Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005 Dec 3;366(9501):1925-34. doi: 10.1016/S0140-6736(05)67704-5. PubMed 16325694 ↗
  • Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. PubMed 28304224 ↗
  • Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 Sep 24;373(13):1274-5. doi: 10.1056/NEJMc1508692. No abstract available. PubMed 26398078 ↗
  • Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP, Wilson PWF. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018 Apr 3;137(14):1435-1446. doi: 10.1161/CIRCULATIONAHA.117.032361. Epub 2018 Jan 12. PubMed 29330214 ↗
  • Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW Jr. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg. 2006 Jun;43(6):1205-10. doi: 10.1016/j.jvs.2006.02.019. PubMed 16765240 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2023, 34 months.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's 34 months is close to that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
May 22, 2020
StartActual
Jul 7, 2020
Primary completionActual
May 11, 2023
CompletionActual
May 11, 2023
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04400409
Lead sponsor
Colorado Prevention Center
Responsible party
Sponsor
First posted
May 22, 2020
Start date
Jul 7, 2020
Primary completion
May 11, 2023
Completion
May 11, 2023
Last update
Feb 8, 2024

Study contacts

Connie Hess, MD
principal investigator · CPC Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion